2nd Annual Symposium

Center for Glomerular Kidney Disease and Novel Experimental Therapeutics

2nd Annual Glom-NExT Symposium

 

 

A message from the Director: 

Thank you for your support of Glom-NExT2, our second symposium spawned from an initiative whose mission is to spearhead targeted, precision medicines for kidney disease, an area of tremendous unmet need.

This year, we were delighted to have once again incredible enthusiasm and an overwhelming demand for participation in our 2nd Annual Symposium called Glom-NExT2.

Our symposium had robust representation from thought leaders in academic centers across the US, incredibly insightful comments by a leader at the FDA, and more than 30 pharma/biotech senior leaders from all across the country.

With this degree of demand and success on a national level, we are pleased to announce Glom-NExT3, which will be held on April 4, 2017 at the Broad Institute of MIT and Harvard. Mark your calendars!

Until then, I welcome your ideas, questions or suggestions for topics to cover in future events.

 

Warm regards,

Anna Greka, MD, PhD
Director, Glom-NExT Center

 



Monday, October 19, 2015


Martin Conference Center
Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115

The theme for this year’s symposium is:


 Thesis, Anti-thesis and Syn-thesis:
How academia and industry perspectives can be synthesized
for the effective pursuit of novel therapeutics


 

* Registration for this event is now closed. *
If you have any questions, please contact Soo Kim at skim72@partners.org or 617-525-5940. 
We look forward to welcoming you to Glom-NExT2!

 

 

 

In last year’s Inaugural Symposium, attended by representatives from more than a dozen pharmaceutical and biotech companies, we heard primarily from academics about the challenges and opportunities in kidney disease therapeutics.

This year, we have invited our industry colleagues to add their perspectives, aiming to foster collaboration and break down longstanding barriers to much-needed novel therapies for kidney disease.

 

 

 

Symposium Program
Honorary Co-Chairs: Drs. Barry M. Brenner and Joseph V. Bonventre 

 

Welcome

9.00 am           Anna Greka, MD, PhD         

 

 

 

 

Session 1. Genetics as a powerful driver of therapeutic discovery
Chairs: Friedhelm Hildebrandt, MD and Martin Pollak, MD

9.10 –  9.30 am Jeffrey Kopp, MD
APOL1 as a therapeutic target for FSGS
9.30 –  9.50 am

Jeffrey Miner, PhD
Alport syndrome therapeutics

9.50 – 10.10 am Lucienne Ronco, PhD
Novel therapeutics for MUC1-associated Kidney Disease (MKD)
10.10 – 10.30 am Corey Hopkins, PhD
Ion channel therapeutics: a medicinal chemist’s perspective
10.30 – 11.00 am Roundtable discussion
Coffee available

 

 

 

 

 

 

 

 

 

 

 

 

Session 2. Keynote Address
Chair: Raymond Harris, MD

11.00 am – 12.00 pm Charles Homcy, MD
Perspectives from an academic cardiologist 
turned biotechnology innovator       

 

 

 

 


Session 3. Working Lunch Roundtable: How can we do better?
Chairs: Lawrence Holzman, MD, Joseph Bonventre, MD, PhD, Louis Brenner, MD, and Brian Perreira, MD

12.00 – 1.00 pm In this brainstorming session, we will discuss how we can promote
academia-industry collaborations and how we can enhance
their impact on novel therapeutics for kidney disease.

 

 

 

 

 

Session 4. The quest for therapeutic targets for kidney diseases 
Chairs: David Salant, MD and Valerie Schumacher, PhD

 1.00 – 1.20 pm

Nick Pullen, PhD

Targeting FSGS and other proteinuric kidney diseases

1.20 – 1.40 pm

Matthew Breyer, MD
Targeting diabetic kidney disease

1.40 – 2.00 pm Michael Maldonado, MD
Immunotherapy and proteinuric kidney disease therapeutics
2.00 – 2.20 pm Jeremy Duffield, MD, PhD
Targeting kidney fibrosis
2. 20 – 2.50 pm

Roundtable discussion
Coffee available

 

 

 

 

 

 

 

 

 

 

 

 

Session 5. Challenges and opportunities for successful clinical trials in kidney disease therapeutics
Chairs: Deb Gipson, MD and Sus Waikar, MD

2.50 – 3.10 pm Matthias Kretzler, MD
The importance of patient registries: NEPTUNE and CureGN
3.10 – 3.30 pm

Astrid Weins, MD, PhD
Challenges and opportunities in novel biomarker development

3.30 – 3.50 pm Howard Trachtman, MD

Clinical trials in kidney disease and the quest for meaningful endpoints

3.50 – 4.10 pm Aliza Thompson, MD
Novel therapeutics for kidney disease and the FDA
4.10 – 5.00 pm Roundtable discussion
Coffee available

 

 

 

 

 

 

 

 

 

 

 

Closing Remarks

5.00 – 5.15 pm  Anna Greka, MD, PhD
Making the case for Syn-thesis

 

 

 

 

Reception will follow at the Martin Conference Center lounge.

 

 

* Registration for this event is now closed. *
If you have any questions, please contact Soo Kim at skim72@partners.org or 617-525-5940. 
We look forward to welcoming you to Glom-NExT2!